We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

100 hedge funds and large institutions have $287M invested in Enanta Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 33 increasing their positions, 44 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more call options, than puts

Call options by funds: $140K | Put options by funds: $68K

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.42% less ownership

Funds ownership: 105.91% → 104.49% (-1.4%)

7% less funds holding

Funds holding: 107 → 100 (-7)

25% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 44

27% less capital invested

Capital invested by funds: $391M → $287M (-$104M)

39% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 18

Holders
100
Holders Change
-7
Holders Change %
-6.54%
% of All Funds
1.44%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
11
Increased
33
Reduced
44
Closed
18
Calls
$140K
Puts
$68K
Net Calls
+$72K
Net Calls Change
+$34K

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$5.53M
2
SCM
Soleus Capital Management
Connecticut
+$2.96M
3
CP
Caligan Partners
New York
+$2.49M
4
KAM
Krensavage Asset Management
New York
+$1.71M
5
BFM
Boothbay Fund Management
New York
+$1.28M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$7.95M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$2.12M
3
AC
Armistice Capital
New York
-$1.89M
4
Northern Trust
Northern Trust
Illinois
-$1.19M
5
Two Sigma Investments
Two Sigma Investments
New York
-$982K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Sio Capital Management
New York
$2.3M – – –
Charles Schwab
27
Charles Schwab
California
$2.13M +$41.1K +3,047 +2%
JP Morgan Chase
28
JP Morgan Chase
New York
$2.06M +$277K +20,499 +15%
Prudential Financial
29
Prudential Financial
New Jersey
$2.04M -$205K -15,200 -9%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$1.67M -$813K -60,194 -32%
EAM
31
Erste Asset Management
Austria
$1.56M – – –
Federated Hermes
32
Federated Hermes
Pennsylvania
$1.14M -$27 -2 -0%
Goldman Sachs
33
Goldman Sachs
New York
$1.1M -$79.4K -5,879 -6%
TI
34
Trexquant Investment
Connecticut
$1.02M -$226K -16,716 -17%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$958K +$117K +8,645 +13%
SEI Investments
36
SEI Investments
Pennsylvania
$946K -$206K -15,230 -17%
AQR Capital Management
37
AQR Capital Management
Connecticut
$778K -$671K -49,701 -45%
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
$775K -$578K -42,841 -42%
N
39
Nuveen
North Carolina
$721K -$456K -33,780 -38%
YIH
40
Y-Intercept (HK)
Hong Kong
$597K +$621K +45,999 New
CSS
41
Cubist Systematic Strategies
Connecticut
$588K +$243K +18,003 +66%
Invesco
42
Invesco
Georgia
$562K -$1.82K -135 -0.3%
Fidelity Investments
43
Fidelity Investments
Massachusetts
$538K +$27.6K +2,041 +5%
Norges Bank
44
Norges Bank
Norway
$528K +$549K +40,700 New
PP
45
PDT Partners
New York
$470K -$47K -3,484 -9%
PI
46
Pennant Investors
New Jersey
$455K – – –
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$451K +$136K +10,075 +41%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$448K +$20.9K +1,548 +5%
PGA
49
Portland Global Advisors
Maine
$430K +$119K +8,810 +36%
AllianceBernstein
50
AllianceBernstein
Tennessee
$388K +$27.1K +2,010 +7%
1
2
3 4 5

ENTA Hedge Fund Activity: Q2 2024 in Review

100 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2024, worth a combined $287M — down 27% from $391M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ENTA and 11 opened new positions — a net loss of 7 holders — while 44 trimmed existing stakes and 33 added.

The largest buyer was Citadel Advisors, adding an estimated $5.53M. The largest seller was Morgan Stanley, cutting an estimated $7.95M.

  • 100 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2024, down from 107 in Q1 2024.
  • Funds reported $287M of Enanta Pharmaceuticals stock for Q2 2024, down 27% quarter-over-quarter.
  • 11 funds opened new Enanta Pharmaceuticals positions in Q2 2024 and 18 closed out, a net change of -7 holders.
  • The largest Enanta Pharmaceuticals buyer in Q2 2024 was Citadel Advisors, an estimated $5.53M added.
  • The largest Enanta Pharmaceuticals seller in Q2 2024 was Morgan Stanley, an estimated $7.95M sold.

Based on aggregated 13F filings for Q2 2024.